Low doses of a cancer drug may be able to act as a preventive drug against the development of Type 1 diabetes, according to new findings.
Scientists have mapped the structure of two key proteins that play a leading role in how a deadly strain of malaria infects its host and spreads disease.
Dutch InteRNA Technologies is collaborating with the Neuroallianz Consortium, an academic industry partnership with Belgium-based UCB and the Rheinische Friedrich-Wilhelms-University of Bonn in Germany, to develop and study microRNA therapeutics in neurodegenerative diseases.
Researchers have turned back the clock on the brain cells of Alzheimer's patients and claim to have generated--for the first time--embryonic-like stem cells taken from frozen brain tissue samples.
Scientists have found how T cells belonging to a special class defend the body against tuberculosis--a finding that could lead to new therapeutic approaches to treating TB, which remains a major cause of death in many parts of the world.
Using an emerging technique called optogenetics, which uses light to stimulate neurons, researchers at the University at Buffalo have found a way to alter alcohol drinking in rodents that mimics human binge drinking behavior.
A faulty gene that causes hyperglycemia in mice may be a determinant of Type 2 diabetes in people, researchers at the University of Illinois at Chicago College of Medicine have found.
After launching a subsidiary in December that will focus on vaccines, Astellas Pharma is showing that it's serious about becoming a player in the vaccines sector.
Six cancer research centers at prestigious U.S. academic institutions have jointly received a $540 million boost in funding from the international Ludwig Cancer Research community.
Cancer Research UK has struck a deal with AstraZeneca to repurpose an experimental therapy originally developed by the drug giant for asthma and study its ability to fight kidney cancer.
NIH announced 6 funding opportunities in so-called high priority research areas, identified by an NIH work group in September 2013. The awards will total $40 million and be announced in September 2014. Applications for funding are due in March.
A team headed by researchers at the University of Pennsylvania has figured out a way to reduce the toxicity of Lou Gehrig's disease by slowing neuron dysfunction in animal models. The discovery could offer a new way to treat the disease, also known as amyotrophic lateral sclerosis, or ALS.
Alzheimer's disease and vascular dementia, the two most common dementias, may be more alike than scientists previously thought.
Researchers at Vanderbilt University have discovered promising drug targets for previously hard-to-treat kinds of melanoma, suggesting that some cancers believed not to have such targets actually do.
The California Institute for Regenerative Medicine voted Dec. 12 to provide $61 million to 6 winners of its third round of Disease Team awards. The winning researchers' work focuses on diseases like leukemia and other solid tumor cancers--such as breast and prostate--that are unresponsive to conventional treatment.
Early research published in peer-reviewed journals is exploratory and largely speculative. But when results from these studies can't be reproduced, science comes under fire. Now a new report suggests that a unifying standards framework could yield more credible scientific results.
The medical community welcomed a budget deal struck Tuesday night by the U.S. Congress, which, if approved, would restore funding to the National Institutes of Health, among other federal programs, that had been slashed under sequestration earlier this year.
Scientists believe that for the first time, they have linked the gene CUX1 to the development of one in every 100 tumors in cancer patients.
International Stem Cell Corp. has found a new way to genetically reprogram mature cells into an embryonic-like state, a technique the Carlsbad, CA-based company believes is a safer and more efficient way of creating induced pluripotent stem cells.
A gene discovery by researchers at Tel Aviv University may predict which people are likely to benefit from commonly prescribed antidepressants known as selective serotonin reuptake inhibitors.